Literature DB >> 29333925

Androgen receptor-independent prostate cancer: an emerging clinical entity.

Ilyas Sahin1, Anthony E Mega1, Benedito A Carneiro1.   

Abstract

Androgen deprivation therapy remains the backbone of prostate cancer treatment given its pivotal role in the pathogenesis of prostate cancer. The growing knowledge of androgen receptor-independent (i.e. AR-null) prostate cancer cells, however, might advance the treatment paradigm of prostate cancer. Here, we examined the results of two recent studies, published in Cancer Cell by Bluemn and Shukla et al., and their impact in the future management of castration-resistant prostate cancer.

Entities:  

Keywords:  Cancer Biology; androgen; castration; independent; medicine; personalized; receptor; resistance

Mesh：

Substances：

Year:  2018        PMID： 29333925      PMCID： PMC5915038          DOI： 10.1080/15384047.2018.1423926

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


  6 in total

Review 1.  Clinical utility of emerging liquid biomarkers in advanced prostate cancer.

Authors:  Gillian Vandekerkhove; Kim N Chi; Alexander W Wyatt
Journal:  Cancer Genet       Date:  2017-08-25

Review 2.  Targeting androgen-independent pathways: new chances for patients with prostate cancer?

Authors:  C Cattrini; E Zanardi; G Vallome; A Cavo; L Cerbone; A Di Meglio; C Fabbroni; M M Latocca; F Rizzo; C Messina; A Rubagotti; P Barboro; F Boccardo
Journal:  Crit Rev Oncol Hematol       Date:  2017-08-30       Impact factor: 6.312

3.  Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.

Authors:  Rajal B Shah; Rohit Mehra; Arul M Chinnaiyan; Ronglai Shen; Debashis Ghosh; Ming Zhou; Gary R Macvicar; Soorynarayana Varambally; Jason Harwood; Tarek A Bismar; Robert Kim; Mark A Rubin; Kenneth J Pienta
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

4.  Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance.

Authors:  Shipra Shukla; Joanna Cyrta; Devan A Murphy; Edward G Walczak; Leili Ran; Praveen Agrawal; Yuanyuan Xie; Yuedan Chen; Shangqian Wang; Yu Zhan; Dan Li; Elissa W P Wong; Andrea Sboner; Himisha Beltran; Juan Miguel Mosquera; Jessica Sher; Zhen Cao; John Wongvipat; Richard P Koche; Anuradha Gopalan; Deyou Zheng; Mark A Rubin; Howard I Scher; Ping Chi; Yu Chen
Journal:  Cancer Cell       Date:  2017-11-16       Impact factor: 31.743

5.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.

Authors:  Eric G Bluemn; Ilsa M Coleman; Jared M Lucas; Roger T Coleman; Susana Hernandez-Lopez; Robin Tharakan; Daniella Bianchi-Frias; Ruth F Dumpit; Arja Kaipainen; Alexandra N Corella; Yu Chi Yang; Michael D Nyquist; Elahe Mostaghel; Andrew C Hsieh; Xiaotun Zhang; Eva Corey; Lisha G Brown; Holly M Nguyen; Kenneth Pienta; Michael Ittmann; Michael Schweizer; Lawrence D True; David Wise; Paul S Rennie; Robert L Vessella; Colm Morrissey; Peter S Nelson
Journal:  Cancer Cell       Date:  2017-10-09       Impact factor: 31.743

6.  Mechanisms of Androgen-Independent Prostate Cancer.

Authors:  Punit Saraon; Andrei P Drabovich; Keith A Jarvi; Eleftherios P Diamandis
Journal:  EJIFCC       Date:  2014-04-28
  6 in total
  2 in total

1.  Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.

Authors:  Ayse Gulten Kantarci; Stephen P Finn; Ezgi Oner; Mustafa Kotmakci; Anne-Marie Baird; Steven G Gray; Bilge Debelec Butuner; Emir Bozkurt
Journal:  J Nanobiotechnology       Date:  2021-03-08       Impact factor: 10.435

2.  RAP80 expression in breast cancer and its relationship with apoptosis in breast cancer cells.

Authors:  Guanghua Jin; Xiaoyun Mao; Zhen Qiao; Bo Chen; Feng Jin
Journal:  Onco Targets Ther       Date:  2019-01-18       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.